Turnaround.
The German Vaccination Commission (Stiko) is considering recommending AstraZeneca's anti-Covid vaccine for those over 65 after a study in Scotland showing its effectiveness for the elderly, its chairman said.
Asked if Stiko could authorize the Swedish-British laboratory's vaccine for all after the encouraging results of this study, Thomas Mertens said: "it is possible and we will do it" in an interview on public television. ZDF Friday evening.
The commission "will very soon publish a new updated recommendation", he said, adding to be still awaiting details from the authors of the study, led by the University of Edinburgh and made public there is a week.
So far, this vaccine, less effective than its messenger RNA competitors, is recommended for those under 65, a decision that has aroused suspicion among the population in Germany, the first country to issue this recommendation, especially since imitated by the France.
"It all went wrong"
The product also remains unpopular in part of Europe, even though the European Medicines Agency (EMA) had approved its use for those over 18, without age limit, in the European Union.
German doctors and public health officials recently appealed for the cheaper and easier to store vaccine to be administered more, as tens of thousands of vials remained unused in the country.
"It all turned out badly," admitted the chairman of the commission, justifying the decision at the end of January not to recommend the vaccine to the elderly by a lack of data at the time.
"We have never criticized the vaccine," which is "very good," he insisted.
READ ALSO>
Coronavirus: AstraZeneca "is not a second-rate vaccine", defends Alain Fischer
The study carried out as part of the vaccination campaign in Scotland showed that four weeks after the administration of a first dose, the risk of hospitalization was reduced by 85% with the Pfizer / BioNTech vaccine and by 94% with AstraZeneca / Oxford, compared to people who did not receive the vaccine.
Among those over 80, one of the most at-risk groups, preliminary combined results of the two vaccines showed an 81% reduction in hospitalizations.
